Halima El Omri
Overview
Explore the profile of Halima El Omri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A ElKourashy S, Soliman D, El Omri A, Y Taha R, Elsabah H, Alashi H, et al.
Hematology
. 2024 Dec;
29(1):2392467.
PMID: 39665684
Background: In MENA region, there is a lack of evidence on Primary Myelofibrosis (PMF), leading to its underrepresentation in medical literature. This study marks the first comprehensive report on PMF...
2.
Elsabah H, Ghasoub R, El Omri H, Benkhadra M, Cherif H, Y Taha R
Front Oncol
. 2024 Jul;
14:1390747.
PMID: 39050574
Introduction: Venetoclax is a BCL-2 inhibitor with proven efficacy in patients with multiple myeloma (MM) and translocation t(11;14). However, its role in plasma cell leukemia (PCL) remains unclear. Herein, we...
3.
Al-Khabori M, Alhuraiji A, Alam A, Khan F, El Omri H, Osman H, et al.
JCO Glob Oncol
. 2024 Jun;
10:e2300165.
PMID: 38843471
Purpose: AML is a heterogeneous hematologic malignancy. Region-specific recommendations for AML management can enhance patient outcomes. This article aimed to develop recommendations for the Gulf Cooperation Council (GCC) countries. Methods:...
4.
Elsabah H, El Omri H, Habas E, Y Taha R, A ElKourashy S, Ibrahim F, et al.
Front Med (Lausanne)
. 2024 Mar;
11:1338552.
PMID: 38444413
Background: Multiple myeloma (MM) is one of the most common hematological malignancies globally, and it is projected to increase in the coming years. It occurs more frequently in males and...
5.
El Omri H, Padmanabhan R, Y Taha R, Kassem N, Elsabah H, Ellahie A, et al.
J Infect Public Health
. 2023 Nov;
17(1):152-162.
PMID: 38029491
Background: The use of ill-suited antibiotics is a significant risk factor behind the increase in the mortality, morbidity, and economic burden for patients who are under treatment for hematological malignancy...
6.
Kassem N, Alshurafa A, Elsabah H, El Omri H
Clin Case Rep
. 2023 Nov;
11(11):e8223.
PMID: 38028081
Erythema nodosum (EN) is a type of panniculitis occurring due to various conditions. It can be associated with certain malignancies or manifest as a side effect of drugs. This article...
7.
Mohamed A, Alkhatib M, Alshurafa A, El Omri H
Hematology
. 2023 Sep;
28(1):2252651.
PMID: 37664905
Background: Cold agglutinin disease (CAD) is immune-mediated hemolytic anemia. The disease is caused by cold reactive autoantibodies that induce hemolysis through the activation of the complement pathway. Most patients with...
8.
Padmanabhan R, El Alaoui Y, Elomri A, Qaraqe M, El Omri H, Taha R
Stud Health Technol Inform
. 2023 Jun;
305:279-282.
PMID: 37387017
The comprehensive epidemiology and global disease burdens reported recently suggest that chronic lymphocytic leukemia (CLL) constitutes 25-30% of leukemias thus being the most common leukemia subtype. However, there is an...
9.
El Alaoui Y, Padmanabhan R, Elomri A, Qaraqe M, El Omri H, Taha R
Stud Health Technol Inform
. 2023 Jun;
305:265-268.
PMID: 37387013
This study suggests a novel Acute Lymphoblastic Leukemia (ALL) diagnostic model, built solely on complete blood count (CBC) records. Using a dataset comprised of CBC records of 86 ALL and...
10.
Padmanabhan R, Elomri A, Taha R, El Omri H, Elsabah H, El Omri A
Int J Environ Res Public Health
. 2023 Jan;
20(1).
PMID: 36612856
Reliable and rapid medical diagnosis is the cornerstone for improving the survival rate and quality of life of cancer patients. The problem of clinical decision-making pertaining to the management of...